Skip to main content
. Author manuscript; available in PMC: 2018 Feb 14.
Published in final edited form as: J Investig Med. 2017 Jun 8;65(7):1057–1061. doi: 10.1136/jim-2017-000445

Table 1.

Laboratory data before and after administration of an SGLT2 inhibitor

Before After p
AST (U/L) 26±8 27±8 0.72
ALT (U/L) 38±21 34±20 0.012
γGTP (U/L) 68±54 42±26 0.013
BUN (mg/dL) 14.1±5.4 16.8±5.2 0.046
Cr (mg/dL) 0.69±0.17 0.74±0.18 0.16
T.Cho (mg/dL) 182±34 171±34 0.039
HDL-C (mg/dL) 51±17 50±17 0.37
TG (mg/dL) 171±87 159±97 0.57
Ht (%) 41±6 38±15 0.54
UA (mg/dL) 5.5±1.5 5.2±1.2 0.22
HbA1c (%) 8.5±1.3 7.5±1.0 0.0003
BW (kg) 82.5±20.2 80.6±20.9 0.013

Before and after administration of SGLT2 inhibitors.

ALT, alanine transaminase; AST, aspartate transaminase; BW, body weight; BUN, blood urea nitrogen/creatinine; γGTP, γ-glutamyltranspeptidase; Cr, creatinine; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein - cholesterol; Ht, hematocrit; SGLT2, sodium-glucose co-transporter 2; T.Cho, total cholesterol; TG, triglyceride; UA, uric acid.